Gilead-Genhouse tie-up among several spanning Pacific: Deals Report

Cross-border deals between East and West were in focus this week, as Western biopharmas continue to tap innovation from the far side of the Pacific.

In a single-asset deal, Gilead Sciences Inc. (NASDAQ:GILD) is paying Suzhou Genhouse Bio Co. Ltd. $80 million up front for worldwide rights to GH31, a clinic-ready molecule that uses synthetic lethality to target MAT2A. Genhouse said GH31 has received regulatory clearance to begin studies in China and the U.S., paving the way for global development across multiple tumor types...